Analysts Set Alector, Inc. (NASDAQ:ALEC) PT at $4.17

Alector, Inc. (NASDAQ:ALEC) has been given an average rating of “Hold” by the eight analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $4.1667.

A number of brokerages have issued reports on ALEC. BTIG Research upgraded Alector from a “neutral” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Tuesday, March 10th. Wall Street Zen cut Alector from a “hold” rating to a “sell” rating in a report on Sunday, March 1st. Morgan Stanley reissued an “underweight” rating on shares of Alector in a research report on Thursday, January 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alector in a report on Wednesday, January 21st.

Institutional Investors Weigh In On Alector

Hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of Alector in the 4th quarter worth about $34,000. Invesco Ltd. grew its holdings in Alector by 45.3% during the 4th quarter. Invesco Ltd. now owns 279,468 shares of the company’s stock valued at $436,000 after purchasing an additional 87,157 shares during the last quarter. Mackenzie Financial Corp raised its position in Alector by 132.7% in the 4th quarter. Mackenzie Financial Corp now owns 660,168 shares of the company’s stock worth $1,001,000 after purchasing an additional 376,456 shares during the period. XTX Topco Ltd raised its position in Alector by 501.8% in the 4th quarter. XTX Topco Ltd now owns 592,839 shares of the company’s stock worth $925,000 after purchasing an additional 494,326 shares during the period. Finally, Ikarian Capital LLC raised its position in Alector by 174.0% in the 4th quarter. Ikarian Capital LLC now owns 2,082,606 shares of the company’s stock worth $3,249,000 after purchasing an additional 1,322,606 shares during the period. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Alector Stock Performance

Alector stock opened at $2.05 on Monday. The company’s 50-day moving average price is $2.02 and its 200-day moving average price is $2.02. Alector has a twelve month low of $0.87 and a twelve month high of $3.40. The company has a quick ratio of 3.83, a current ratio of 3.83 and a debt-to-equity ratio of 0.30. The company has a market cap of $226.24 million, a PE ratio of -1.47 and a beta of 0.58.

Alector (NASDAQ:ALEC) last announced its earnings results on Wednesday, February 25th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.05. The firm had revenue of $6.24 million for the quarter, compared to analysts’ expectations of $1.78 million. Alector had a negative net margin of 679.16% and a negative return on equity of 224.96%. On average, equities research analysts forecast that Alector will post -1.88 EPS for the current fiscal year.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.